ADVFN ADVFN

Hot Features

Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Medicenna Therapeutics Corporation (QX)

Medicenna Therapeutics Corporation (QX) (MDNAF)

0,27635
-0,01365
( -4,71% )
Mis à jour : 17:59:44

Medicenna Therapeutics Corporation (QX) (MDNAF) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
0,27635
( -4,71% )
Prix Achat
0,2674
Prix Vente
0,2767
Volume échangé
31 030
Volume moyen (3 m)
US$ 105 549
Volume financier
US$ 8 516
0,2733 Fourchette du Jour 0,27805
0,25 Plage de 52 semaines 1,43
Cap du marché
Valeur d'Entreprise
30,327M
Clôture Veille
0,29
Ouverture
0,2733
Dernière Transaction
30
@
0.27605
Dernière heure de transaction
17:04:26
VWAP
0,274437
Chiffre d'affairess (LTM)
-
Bénéfice net (LTM)
-18,41M
Actions en circulation
92 300 201
Flottant (%)
80,79%
Détention Institutionnelle (%)
-
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
-1,79
Ratio Cours/Ventes (P/S)
-
Bénéfice par action (BPA)
-0,22
Bêta
1,89

À propos de Medicenna Therapeutics Corporation (QX)

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for... Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada. Show more

Secteur
Healthcare
Industrie
Biotechnology & Life Sciences
Siège social
Toronto, Canada
Fondé
-
Medicenna Therapeutics Corporation (QX) est coté dans le secteur Healthcare de la OTC Markets avec le ticker MDNAF. Le dernier cours de clôture d'Medicenna Therapeutics (QX) était de US$0,29. Au cours de la dernière année, les actions de Medicenna Therapeutics (QX) ont été négociées dans une fourchette de prix de US$ 0,25 à US$ 1,43.

Medicenna Therapeutics (QX) compte actuellement 92 300 201 actions en circulation. La capitalisation boursière d'Medicenna Therapeutics (QX) est de US$25,51 million. Medicenna Therapeutics (QX) a un ratio cours/bénéfice (ratio PE) de -1.79.

MDNAF Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.001750.6372906045160.27460.30790.2551373100.28332663CS
4-0.03121-10.14761347380.307560.320.25730300.28668634CS
12-0.18929-40.65157632510.465640.529880.25873700.35660423CS
26-0.42165-60.40830945560.6980.7550.25818440.48239619CS
52-0.38365-58.12878787880.661.430.25834260.68618931CS
1560.1123568.5060975610.1642.20.158894840.98011692CS
260-4.39365-94.08244111354.674.670.158888210.98011692CS

MDNAF - Frequently Asked Questions (FAQ)

What is the current Medicenna Therapeutics Corporation (QX) share price?
The current share price of Medicenna Therapeutics Corporation (QX) is US$ 0,27635
How many Medicenna Therapeutics Corporation (QX) shares are in issue?
Medicenna Therapeutics Corporation (QX) has 92 300 201 shares in issue
What is the market cap of Medicenna Therapeutics Corporation (QX)?
The market capitalisation of Medicenna Therapeutics Corporation (QX) is USD 25,51M
What is the 1 year trading range for Medicenna Therapeutics Corporation (QX) share price?
Medicenna Therapeutics Corporation (QX) has traded in the range of US$ 0,25 to US$ 1,43 during the past year
What is the PE ratio of Medicenna Therapeutics Corporation (QX)?
The price to earnings ratio of Medicenna Therapeutics Corporation (QX) is -1,79
What is the registered address of Medicenna Therapeutics Corporation (QX)?
The registered address for Medicenna Therapeutics Corporation (QX) is 2 Bloor Street West, Toronto, Ontario, M4W 3E2
What is the Medicenna Therapeutics Corporation (QX) website address?
The website address for Medicenna Therapeutics Corporation (QX) is www.medicenna.com
Which industry sector does Medicenna Therapeutics Corporation (QX) operate in?
Medicenna Therapeutics Corporation (QX) operates in the Biotechnology & Life Sciences sector

MDNAF Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion